(ChemotherapyAdvisor) – Patients with renal cell carcinoma (RCC) and non-O blood type have worse overall survival, according to the first report of this relationship at the American Urological Association Annual Meeting in Atlanta, GA, on May 21.
“A number of potential molecular mechanisms may explain this relationship and further studies will be needed to understand the biology behind this association,” noted Samuel D. Kaffenberger, MD, of Vanderbilt University, Nashville, TN.
He pointed to evidence from nonurologic malignancies suggesting ABO blood type may be a risk factor for both cancer incidence and mortality. “For example, breast cancer patients with O blood type appear to have significantly better overall survival than those with non-O blood types.”
To determine whether ABO blood type was associated with overall survival in patients undergoing nephrectomy for RCC, Dr. Kaffenberger and colleagues analyzed prospectively collected data and identified 923 consecutive patients who underwent radical or partial nephrectomy for locoregional RCC from 1997–2008. Median follow-up was 28.7 months and median survival, the primary outcome measure, 92 months.
ABO blood group was found to be randomly distributed throughout all clinicopathologic variables — age, gender, ASA classification, tumor stage, Fuhrman grade, lymph node status, preoperative anemia, transfusion status, hypoalbuminemia, and blood type (O vs. non-O) — except race, where nonwhite individuals had a higher prevalence of type O (P=0.021).
On univariate analysis, age, ASA classification, tumor stage, grade, nodal disease, anemia, hypoalbuminemia, and blood group met inclusion for multivariate analysis (P<0.1). In multivariate analysis, non-O blood type was independently associated with worse overall survival (HR 1.68, P=0.04) after correcting for other covariates, he concluded.